Related Experiment Video
Updated: Aug 18, 2026
Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
Published on: April 1, 2019
Photodynamic therapy of eye diseases
1Tufts University School of Medicine, Department of Vitreoretinal Surgery, New England Eye Center, 750 Washington Street, Box 450, Boston, MA 02111, USA.
Abstract:
Photodynamic therapy is presently being used to treat several cutaneous cancers. The production of new second generation photosensitizers with better absorption spectra and systemic tolerance has lead to active investigation of these compounds in ophthalmology. The selective tissue damage with PDT is achieved by sequestration of the photosensitizer in the target tissue and focal activation of the photosensitizer by low energy directed light. The potential uses for PDT include the treatment of ocular tumors, neovascularization and ciliary body ablation. Visudyne already has been approved by the FDA for the treatment of subfoveal choroidal neovascularization, and many patients already have been treated with this drug.
Insights
Photodynamic therapy (PDT) shows promise for treating eye conditions. New photosensitizers improve PDT
Area of Science:
- Ophthalmology
- Oncology
- Photochemistry
Background:
- Photodynamic therapy (PDT) is established for cutaneous cancers.
- Advancements in photosensitizers offer improved absorption and tolerance.
- PDT utilizes targeted light activation for selective tissue damage.
Purpose of the Study:
- Investigate the application of novel photosensitizers in ophthalmology.
- Explore PDT for treating ocular tumors and neovascularization.
- Assess PDT's potential for ciliary body ablation.
Main Methods:
- Utilizing second-generation photosensitizers with enhanced properties.
- Employing low-energy directed light for focal activation.
- Targeting photosensitizer sequestration within ocular tissues.
Main Results:
- Visudyne, an FDA-approved PDT drug, is used for subfoveal choroidal neovascularization.
- Numerous patients have been successfully treated with Visudyne.
- PDT demonstrates potential for various ophthalmic applications.
Conclusions:
- Second-generation photosensitizers are expanding PDT's role in ophthalmology.
- PDT offers a targeted approach for treating ocular diseases.
- The efficacy of PDT is supported by existing FDA approvals and patient treatments.
More Related Videos
11:04An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
07:36Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
Published on: July 3, 2025
